Related Experiment Video

Updated: Apr 17, 2026

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects
07:37

An Integrated Raman Spectroscopy and Mass Spectrometry Platform to Study Single-Cell Drug Uptake, Metabolism, and Effects

Published on: January 9, 2020

10.1K

Pharmacogenomics toward personalized tamoxifen therapy for breast cancer

Hitoshi Zembutsu

    Pharmacogenomics
    |February 26, 2015
    PubMed

    Insights

    Genetic variations in CYP2D6 enzyme activity impact tamoxifen treatment effectiveness for breast cancer. Adjusting tamoxifen dosage based on CYP2D6 genotype can help maintain optimal endoxifen levels in patients with reduced enzyme function.

    Area of Science:

    • Pharmacogenomics
    • Oncology
    • Drug Metabolism

    Background:

    • Tamoxifen is a key treatment for estrogen receptor-positive breast cancer.
    • CYP2D6 enzyme is crucial for converting tamoxifen to its active metabolite, endoxifen.
    • Genetic variations in CYP2D6 can affect enzyme activity and tamoxifen efficacy.

    Purpose of the Study:

    • To review critical issues in pharmacogenomic studies of tamoxifen.
    • To summarize the association between CYP2D6 genotype and tamoxifen efficacy.
    • To discuss the clinical implications of CYP2D6 variations in breast cancer treatment.

    Main Methods:

    • Literature review of pharmacogenomic studies on tamoxifen and CYP2D6.
    • Analysis of studies investigating the link between CYP2D6 genotype and clinical outcomes.
    • Examination of evidence supporting tamoxifen dose adjustment based on CYP2D6 genotype.

    Main Results:

    • Many studies link reduced CYP2D6 activity due to genetic variation with poorer outcomes in tamoxifen-treated breast cancer patients.
    • Some studies report conflicting results regarding the CYP2D6 genotype-clinical outcome association.
    • Dose adjustment of tamoxifen based on CYP2D6 genotype can ensure effective endoxifen levels in individuals with reduced or null alleles.

    Conclusions:

    • CYP2D6 genotype plays a significant role in tamoxifen efficacy.
    • Pharmacogenomic testing for CYP2D6 may guide tamoxifen therapy decisions.
    • Personalized tamoxifen dosing strategies based on CYP2D6 genotype are warranted to optimize breast cancer treatment outcomes.
    Keywords:
    ABCC2C10orf11CYP2D6dose adjustmentendoxifenpharmacogenomicstamoxifen

    More Related Videos

    Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

    Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

    Published on: June 18, 2015

    13.9K
    Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

    Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

    Published on: June 13, 2014

    17.2K

    Related Concept Videos

    Pharmacogenomics: Identification of New Drug Targets01:29

    Pharmacogenomics: Identification of New Drug Targets

    Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
    95
    Pharmacogenetics and Pharmacogenomics: Overview01:29

    Pharmacogenetics and Pharmacogenomics: Overview

    Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
    194
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    72
    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

    Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

    Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
    132
    Pharmacogenetics of Drug Metabolism: Overview01:27

    Pharmacogenetics of Drug Metabolism: Overview

    Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
    157
    Combination Therapies and Personalized Medicine02:50

    Combination Therapies and Personalized Medicine

    Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
    The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
    6.4K